452 related articles for article (PubMed ID: 24292068)
1. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.
Hudak JE; Canham SM; Bertozzi CR
Nat Chem Biol; 2014 Jan; 10(1):69-75. PubMed ID: 24292068
[TBL] [Abstract][Full Text] [Related]
2. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
3. A Developed NK-92MI Cell Line with Siglec-7
Huang CH; Liao YJ; Fan TH; Chiou TJ; Lin YH; Twu YC
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29617289
[TBL] [Abstract][Full Text] [Related]
4. Immunology: glyco-engineering 'super-self'.
Macauley MS; Paulson JC
Nat Chem Biol; 2014 Jan; 10(1):7-8. PubMed ID: 24346034
[TBL] [Abstract][Full Text] [Related]
5. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
6. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
7. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
Blood Adv; 2022 Jun; 6(11):3352-3366. PubMed ID: 35294519
[TBL] [Abstract][Full Text] [Related]
8. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
9. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
10. Precision glycocalyx editing as a strategy for cancer immunotherapy.
Xiao H; Woods EC; Vukojicic P; Bertozzi CR
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10304-9. PubMed ID: 27551071
[TBL] [Abstract][Full Text] [Related]
11. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells.
Adeniji OS; Kuri-Cervantes L; Yu C; Xu Z; Ho M; Chew GM; Shikuma C; Tomescu C; George AF; Roan NR; Ndhlovu LC; Liu Q; Muthumani K; Weiner DB; Betts MR; Xiao H; Abdel-Mohsen M
PLoS Pathog; 2021 Nov; 17(11):e1010034. PubMed ID: 34762717
[TBL] [Abstract][Full Text] [Related]
12. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity
Hong S; Yu C; Rodrigues E; Shi Y; Chen H; Wang P; Chapla DG; Gao T; Zhuang R; Moremen KW; Paulson JC; Macauley MS; Wu P
ACS Cent Sci; 2021 Aug; 7(8):1338-1346. PubMed ID: 34471678
[TBL] [Abstract][Full Text] [Related]
14. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
[TBL] [Abstract][Full Text] [Related]
15. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
16. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
Ikehara Y; Ikehara SK; Paulson JC
J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
[TBL] [Abstract][Full Text] [Related]
17. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
18. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
[TBL] [Abstract][Full Text] [Related]
19. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
[TBL] [Abstract][Full Text] [Related]
20. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
